Lena Birgitta Degling Wikingsson
Director/Board Member chez ALZINOVA AB
Profil
Lena Birgitta Degling Wikingsson is currently the Chief Executive Officer at Dilafor AB since 2011.
She is also the Chairman at Simplexia AB since 2010 and an Independent Director at Alzinova AB since 2020.
Additionally, she holds the position of Director at CellProtect Nordic Pharmaceuticals AB, XNK Therapeutics AB, and Dilafor Incentive AB.
Dr. Degling Wikingsson is also an Independent Director at Biosergen AB since 2021.
In her former positions, Dr. Degling Wikingsson served as the Chief Executive Officer at Avaris AB from 2007 to 2011.
She was also the Chairman at NextCell Pharma AB and a Non-Executive Director at Eurocine Vaccines AB from 2012 to 2016.
Furthermore, she held positions as a Principal at Active Biotech AB, SBL Vaccin AB, and Accuro Immunology AB.
Prior to that, she was the President at Independent Pharmaceutica AB from 2002 to 2010 and worked as a Principal at Medical Products Group, Inc.Dr. Degling Wikingsson obtained her graduate and doctorate degrees from the University of Uppsala.
Postes actifs de Lena Birgitta Degling Wikingsson
| Sociétés | Poste | Début |
|---|---|---|
| ALZINOVA AB | Director/Board Member | 01/01/2020 |
| BIOSERGEN AB | Director/Board Member | 01/01/2021 |
Dilafor AB
 Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | Chief Executive Officer | 18/05/2011 |
CellProtect Nordic Pharmaceuticals AB
 CellProtect Nordic Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Part of XNK Therapeutics AB, CellProtect Nordic Pharmaceuticals AB is a clinical-stage biotechnology company based in Huddinge, SE. CellProtect Nordic Pharmaceuticals is one of the pioneering companies in the field of cell therapy, developing unique and individualized natural killer (NK) cell-based cancer therapies. The Swedish company has built a tailor-made GMP clean room facility for manufacturing clinical products and is currently evaluating its lead product, evencaleucel, in a randomized, controlled, phase II study for the treatment of multiple myeloma. The private company was founded in 2012 and the CEO is Johan Liwing. | Director/Board Member | - |
XNK Therapeutics AB
 XNK Therapeutics AB Pharmaceuticals: MajorHealth Technology XNK Therapeutics AB operates as a technology platform which leads research on NK cells at Karolinska Institutet in Stockholm. The company was founded in 2012 and is headquartered in Huddinge, Sweden. | Director/Board Member | 04/10/2021 |
| Dilafor Incentive AB | Director/Board Member | - |
Simplexia AB
 Simplexia AB BiotechnologyHealth Technology Simplexia AB is a company based in Gothenburg, Sweden that aims to launch the first vaccine for the treatment and prevention of genital herpes. The Swedish company is driven by the goal to curtail and treat infection with herpes simplex virus (HSV), one of the world's most prevalent sexually transmitted diseases. The team at Simplexia is composed of experts in pharmaceutical development, including Prof. Jan-Åke Liljeqvist and the Department of Virology at the Sahlgrenska Academy. The vaccine is based on research that showed glycoproteins from HSV-1 and 2, when administered as a vaccine, are highly immunogenic and provide protection in mouse models. | Chairman | 01/01/2010 |
Anciens postes connus de Lena Birgitta Degling Wikingsson
| Sociétés | Poste | Fin |
|---|---|---|
| EUROCINE VACCINES AB | Director/Board Member | 01/01/2016 |
Avaris AB
 Avaris AB Miscellaneous Commercial ServicesCommercial Services Avaris was founded in 2001 by research teams at the Karolinska Institute and Karolinska Innovations AB. The company is based on four proprietary technology platforms within cell and gene therapy. Avaris drives the research development and commercialization of new therapies in close collaboration with the founders, research teams, and strategic partners. The company is well positioned in cell and gene therapy field for chronic infections, cancer and inherited diseases. Avaris vision is to become the number one supplier of individualized cell and gene therapy treatments in northern Europe. In order to reach this goal it is exploring possibilities to acquire, or in license cell therapy technologies that complement the in house growth. Avaris is also open to partnering possibilities. | Chief Executive Officer | 01/12/2011 |
| ░░░░░░░░░░░ ░░░░░░░░░░░░░ ░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░ ░░ | ░░░░░░░░ | - |
| ░░░░░░ ░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Lena Birgitta Degling Wikingsson
| University of Uppsala | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| EUROCINE VACCINES AB | Health Technology |
| ACTIVE BIOTECH AB | Health Technology |
| NEXTCELL PHARMA AB | Health Technology |
| BIOSERGEN AB | Health Technology |
| ALZINOVA AB | Health Technology |
| Entreprise privées | 10 |
|---|---|
SBL Vaccin AB
 SBL Vaccin AB Pharmaceuticals: MajorHealth Technology SBL Vaccin AB manufactures and distributes vaccines. Its products are used for the treatment of polio, diarrhoea, and cholera diseases. The company distributes products to the healthcare centers, hospitals, schools, and industrial healthcare units. SBL Vaccin was founded in 1957 and is located in Solna, Sweden. | Health Technology |
Accuro Immunology AB
 Accuro Immunology AB Pharmaceuticals: MajorHealth Technology Accuro Immunology AB develops and manufactures active immunotherapy products. The firm's products help to treat the patients suffering from problems with immune escape/evasion. The company was founded by Peter Gunnar Maurits Wolpert and Elisabeth Wolpert in 1999 and is headquartered in Stockholm, Sweden. | Health Technology |
Independent Pharmaceutica AB
 Independent Pharmaceutica AB Medical DistributorsDistribution Services Independent Pharmaceutica AB is a privately owned company. The major owners are Karolinska Investment Fund, LH Advisory, Sandin &Co and The Foundation for Baltic and East European Studies (Östersjöstiftelsen). Independent Pharmaceutica aims to provide pharmacological solutions for treatment of nicotine addiction. The company is spun out of research from the Karolinska Institutet in Stockholm, Sweden. Tobacco use is the leading preventable cause of morbidity and premature death in the world.Currently over 1.2 billion people smoke worldwide and the number of annual deaths from tobacco-related diseases is over 4 million and rising. The costs for society are huge. With the new vaccine Niccine® against nicotine addiction, the health condition of millions of patients is expected to be improved. | Distribution Services |
Medical Products Group, Inc.
 Medical Products Group, Inc. Medical DistributorsDistribution Services Medical Products Group, Inc. provided medical equipment and services. The company was founded in 2000 and headquartered in Dixon, IL. | Distribution Services |
Avaris AB
Avaris AB Miscellaneous Commercial ServicesCommercial Services Avaris was founded in 2001 by research teams at the Karolinska Institute and Karolinska Innovations AB. The company is based on four proprietary technology platforms within cell and gene therapy. Avaris drives the research development and commercialization of new therapies in close collaboration with the founders, research teams, and strategic partners. The company is well positioned in cell and gene therapy field for chronic infections, cancer and inherited diseases. Avaris vision is to become the number one supplier of individualized cell and gene therapy treatments in northern Europe. In order to reach this goal it is exploring possibilities to acquire, or in license cell therapy technologies that complement the in house growth. Avaris is also open to partnering possibilities. | Commercial Services |
Dilafor AB
Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | Health Technology |
CellProtect Nordic Pharmaceuticals AB
CellProtect Nordic Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Part of XNK Therapeutics AB, CellProtect Nordic Pharmaceuticals AB is a clinical-stage biotechnology company based in Huddinge, SE. CellProtect Nordic Pharmaceuticals is one of the pioneering companies in the field of cell therapy, developing unique and individualized natural killer (NK) cell-based cancer therapies. The Swedish company has built a tailor-made GMP clean room facility for manufacturing clinical products and is currently evaluating its lead product, evencaleucel, in a randomized, controlled, phase II study for the treatment of multiple myeloma. The private company was founded in 2012 and the CEO is Johan Liwing. | Health Technology |
XNK Therapeutics AB
XNK Therapeutics AB Pharmaceuticals: MajorHealth Technology XNK Therapeutics AB operates as a technology platform which leads research on NK cells at Karolinska Institutet in Stockholm. The company was founded in 2012 and is headquartered in Huddinge, Sweden. | Health Technology |
Simplexia AB
Simplexia AB BiotechnologyHealth Technology Simplexia AB is a company based in Gothenburg, Sweden that aims to launch the first vaccine for the treatment and prevention of genital herpes. The Swedish company is driven by the goal to curtail and treat infection with herpes simplex virus (HSV), one of the world's most prevalent sexually transmitted diseases. The team at Simplexia is composed of experts in pharmaceutical development, including Prof. Jan-Åke Liljeqvist and the Department of Virology at the Sahlgrenska Academy. The vaccine is based on research that showed glycoproteins from HSV-1 and 2, when administered as a vaccine, are highly immunogenic and provide protection in mouse models. | Health Technology |
| Dilafor Incentive AB |
